Global Treatment Access International HIFU operates treatment centers across North America, the Caribbean, Mexico, Europe, Asia, and South America, providing multiple on-the-ground opportunities to introduce or expand sales of the Sonablate 500 system in regions with growing demand for prostate cancer treatments.

Emerging Market Opportunity With the Sonablate 500 approved in over 30 countries beyond the U.S., there is significant potential for sales expansion into international markets, especially in regions with limited access to advanced minimally invasive prostate cancer treatments.

Research and Education Partnering with medical institutions and treatment centers focused on innovative urology solutions can open avenues for training, demonstrations, and increased adoption of HIFU technology among healthcare providers seeking advanced prostate cancer therapies.

Competitive Positioning Compared to larger competitors like EDAP TMS, International HIFU’s focus on international markets and specialized treatment centers presents opportunities to carve out niche market segments and benefit from regional demand for non-invasive prostate treatments.

Growth and Investment Despite current revenue under one million dollars, targeted sales efforts focusing on international adoption and expanding treatment center networks could accelerate revenue growth, presenting a promising opportunity for sales development and investor interest in scaling operations.